Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance

Vanguard Total International Stock Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Vanguard Total International Stock Index Fund ETF — how do they compare? Sanofi SA trades at $43.6 (market cap $104.57B), while Vanguard Total International Stock Index Fund ETF trades at $87.06. The key difference: Sanofi SA pays a 5.56% dividend while Vanguard Total International Stock Index Fund ETF pays none, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.

SNYVXUS
Market Cap
$104.57B
Sector
HealthSector/Thematic
52-Week High
$52.34$87.21
52-Week Low
$41.33$70.87
Enterprise Value
$124.48B
Dividend Yield
5.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.

SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.

Vanguard Total International Stock Index Fund ETF

VXUS trades at $87.21, up 1.03% with strong bullish technical signals from moving averages. The ETF offers broad international diversification with over 8,700 non-U.S. stocks, recently delivering 27.82% total returns over the past year according to Seeking Alpha (August 8, 2026). Institutional interest is growing with multiple firms increasing positions, while analysts highlight its valuation discount to U.S. equities.

The outlook remains positive given international diversification benefits and institutional accumulation, though RSI levels suggest potential near-term consolidation. Key risks include global economic volatility and currency fluctuations. Wall Street sentiment leans bullish with Seeking Alpha maintaining a Buy rating, supported by the ETF's low expense ratio and comprehensive market exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY

About Vanguard Total International Stock Index Fund ETF

VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.

Read more on VXUS